Divi's Laboratories (DIVISLAB.NS) Saham Harga

Divi's Laboratories Harga

NSE·DITUTUP
11.023,00
​
Pasar ditutup

Selama 19 tahun terakhir pendapatan Divi's Laboratories tumbuh 18,4% per tahun, mencapai 93,60 miliar INR. Laba per saham tumbuh 19,8% per tahun selama 19 tahun terakhir. Bagi Divi's Laboratories, margin bersih sebesar 23,4% turun dibanding 28,5% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 0,27%. Rasio pembayaran sekitar 36% dari laba. Dividen tumbuh 24,0% per tahun selama 19 tahun terakhir. Target harga konsensus 12 bulan untuk Divi's Laboratories adalah 7.012,50 INR, sekitar di bawah harga saat ini 36,4%. Dari 36 analis, 20 merekomendasikan beli — konsensus keseluruhan Beli.

Harga saham Divi's Laboratories

Akses data ini lewat Eulerpool API

100.000 permintaan/bulan gratis · tanpa kartu

Model bisnis dan analisis saham Divi's Laboratories

Divi's Laboratories Ltd. adalah perusahaan farmasi yang berkantor pusat di Hyderabad, India. Didirikan pada tahun 1990, perusahaan ini telah menjadi salah satu produsen utama bahan aktif dan formulasi untuk industri farmasi dalam beberapa tahun terakhir. Perusahaan ini didirikan oleh Dr. Murali Divi, yang membangun perusahaan berdasarkan prinsip-prinsip kualitas, teknologi, dan inovasi. Divi's Laboratories kini memiliki sekitar 13.000 karyawan dan mengoperasikan fasilitas produksi di India dan Amerika Serikat. Perusahaan ini beroperasi di berbagai sektor, termasuk obat generik, sintesis khusus, penelitian dan pengembangan, serta nutrasetika. Produk-produknya digunakan di seluruh dunia dan telah disetujui di lebih dari 95 negara. Divi's Laboratories menerapkan model rantai pasok terintegrasi vertikal, memproduksi bahan aktif berkualitas tinggi dan mengembangkan formulasi sendiri untuk industri farmasi. Perusahaan selalu mengandalkan teknologi inovatif dan peningkatan berkelanjutan terhadap kualitas produk. Portofolio produknya mencakup beragam bahan aktif untuk berbagai area terapeutik, seperti antibiotik, antidepresan, antihipertensi, antidiabetik, agen penurun lipid statis, dan antipsikotik. Divi's Laboratories memiliki fasilitas produksi berteknologi canggih, kontrol kualitas yang ketat, serta fasilitas analitik mutakhir untuk semua bahan farmasi. Selain bahan aktif, perusahaan ini juga dikenal atas layanan sintesis khusus, yang melibatkan produksi bahan aktif sesuai spesifikasi pelanggan untuk industri farmasi. Divi's Laboratories menawarkan layanan yang disesuaikan dengan kebutuhan spesifik pelanggan, mulai dari pengembangan bahan aktif dan formulasi baru hingga produksi dalam jumlah kecil atau menengah. Dalam bidang penelitian dan pengembangan, Divi's Laboratories bekerja sama erat dengan institusi akademik dan perusahaan farmasi lainnya untuk memanfaatkan pengetahuan ilmiah terkini dan mengembangkan produk inovatif. Perusahaan mengalokasikan dana signifikan untuk penelitian dan pengembangan setiap tahunnya. Selain bahan aktif dan layanan sintesis khusus, Divi's Laboratories juga menawarkan berbagai produk nutrasetika. Produk-produk ini, seperti vitamin, mineral, dan suplemen makanan lainnya, digunakan untuk mendukung gaya hidup sehat. Secara ringkas, Divi's Laboratories adalah perusahaan farmasi berbasis India yang mengkhususkan diri dalam pembuatan bahan aktif dan formulasi untuk industri farmasi. Perusahaan beroperasi sesuai standar kualitas tertinggi dan mengandalkan teknologi inovatif serta pengembangan produk yang berkelanjutan. Cakupan produk yang luas dan layanan sintesis khusus memberikan solusi yang disesuaikan bagi pelanggan. Divi's Laboratories merupakan penyedia bahan aktif terkemuka dan telah membangun reputasi kuat di industri farmasi dan nutrasetika berkat kualitas tinggi dan produktivitasnya.

Pertanyaan yang sering diajukan tentang saham Divi's Laboratories

The business model of Divi's Laboratories Ltd revolves around the manufacture and supply of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies worldwide. With a focus on quality, innovation, and cost-effective production, Divi's Labs caters to a wide range of therapeutic segments including generics, custom synthesis, and development of new molecules. By leveraging its strong research and development capabilities, cutting-edge technology, and state-of-the-art manufacturing facilities, Divi's Labs has established itself as a trusted supplier in the global pharmaceutical industry.

Divi's Laboratories Ltd is primarily active in the pharmaceutical industry.

The main competitors of Divi's Laboratories Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, and Cipla Ltd.

Divi's Laboratories Ltd is an Indian pharmaceutical company that was founded in 1990. It is headquartered in Hyderabad, Telangana. The company specializes in the research, development, and manufacturing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). Divi's Laboratories has a strong focus on quality with a global customer base and is recognized for its state-of-the-art manufacturing facilities. Over the years, the company has consistently grown and expanded its product portfolio. Divi's Laboratories is committed to innovation, research, and delivering high-quality healthcare solutions to meet the needs of patients worldwide.

Divi's Laboratories Ltd has achieved numerous significant milestones throughout its journey. Notably, the company has consistently demonstrated excellence in the pharmaceutical sector since its establishment. Divi's Laboratories Ltd has successfully garnered a strong reputation for its high-quality manufacturing practices and commitment to innovation. The company has also gained several certifications, including ISO 9001, ISO 14001, and OHSAS 18001, further solidifying its credibility. Moreover, Divi's Laboratories Ltd has expanded its operations globally, establishing a strong presence in various international markets. These incredible achievements highlight Divi's Laboratories Ltd's unwavering dedication to delivering exceptional pharmaceutical solutions while maintaining the highest standards of quality and compliance.

Divi's Laboratories Ltd is primarily present in India, with its headquarters located in Hyderabad. The company operates multiple manufacturing facilities in different locations across India, including Visakhapatnam, Hyderabad, and Mahad. Divi's Laboratories Ltd focuses on manufacturing and supplying active pharmaceutical ingredients (APIs) and intermediates globally. It has a strong presence in various countries and regions, including the United States, Europe, Japan, Korea, and several emerging markets. With its commitment to quality and adherence to international regulatory standards, Divi's Laboratories Ltd has established itself as a trusted supplier of pharmaceutical products worldwide.

Divi's Laboratories Ltd is committed to upholding values of excellence, integrity, and innovation. With a strong corporate philosophy centered around quality and customer satisfaction, the company continually strives to provide top-notch pharmaceutical products and services. Divi's Laboratories Ltd focuses on research and development to ensure cutting-edge solutions and advancements in the field. The company's emphasis on ethical practices and transparency reflects its commitment to maintaining strong relationships with stakeholders. Divi's Laboratories Ltd's dedication to continuous improvement and market leadership makes it a preferred choice for investors seeking a reliable and progressive pharmaceutical company.

Analis saat ini menetapkan target harga rata-rata 6.987,18 INR untuk saham Divi's Laboratories (median: 7.012,50 INR), yaitu -36,6 % terhadap harga terbaru. Konsensus didasarkan pada 36 peringkat analis.

36 analis saat ini menilai saham Divi's Laboratories: 21 merekomendasikan beli, 6 tahan, dan 9 jual. Untuk 2026, analis memperkirakan Divi's Laboratories menghasilkan pendapatan 106,46 miliar INR dan laba per saham 115,11 INR.

Dengan kurs saat ini, saham Divi's Laboratories diperdagangkan pada 107,57 EUR (11.023,00 INR).

Saham Divi's Laboratories (DIVISLAB.NS) tercatat di 2 bursa, termasuk: NSE (Indien) (DIVISLAB.NS).

Divi's Laboratories Ltd is an Indian company that manufactures pharmaceutical active ingredients and intermediates for the global market. The company was founded in 1990 and is headquartered in Hyderabad, India. Divi's Laboratories' business model is based on extensive research and development and high production capacity. The company follows a vertically integrated production strategy, engaging in the development of new active ingredients and the production of intermediates and finished products. Divi's Laboratories serves a variety of industries such as the pharmaceutical and cosmetic industries, agriculture, and the food industry. The company offers a wide range of products such as antibiotics, antidepressants, vitamins, and folic acid for the pharmaceutical industry. For the cosmetic and food industries, the company offers emulsifiers, fragrances and flavors, as well as dyes and sunscreens. The company has two modern manufacturing facilities with a total capacity of over 500 tons per year. Divi's Laboratories continuously invests in state-of-the-art production facilities to increase capacity and productivity. Divi's Laboratories specializes in the manufacture of pharmaceutical active ingredients and intermediates and therefore enjoys a good reputation in the industry. The company has established a strong position in the market in recent years and has expanded into various countries such as the USA, Europe, and Asia. The company is also successful in research and development of new products. Divi's Laboratories has its own research and development department that develops new synthetic methods and processes for the production of active ingredients. The company works closely with customers to produce customized products for their specific requirements. Furthermore, Divi's Laboratories is involved in the research of natural substances that can be used in the medical field. The company has its own department for biotechnological research and development to isolate new natural substances and investigate their potential for medical application. In summary, Divi's Laboratories' business model is very successful and focused on a wide range of products and extensive research and development. The company has established a strong position in the global market for pharmaceutical active ingredients and intermediates and is on track to further expand its position.

Pendapatan diperkirakan dari Divi's Laboratories adalah 106,46 miliar INR. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari Divi's Laboratories adalah 30,53 miliar INR. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) Divi's Laboratories saat ini adalah 95,76. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Divi's Laboratories.

Rasio harga-terhadap-penjualan (PSR) Divi's Laboratories saat ini adalah 27,46. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Divi's Laboratories.

Skor Kualitas AlleAktien untuk Divi's Laboratories adalah 7/10.

ISIN dari Divi's Laboratories adalah INE361B01024. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

Ticker dari Divi's Laboratories adalah DIVISLAB.NS. Simbol ticker digunakan untuk memperdagangkan saham Divi's Laboratories di bursa saham.

Nilai WajarTerminal
10.141,16 INR
Penilaian Berlebihan/KurangTerminal
Dinilai secara wajar
Sektor
Industri
Alat & Layanan untuk Ilmu Hayati
Jumlah Saham
Karyawan
Pendapatan per Karyawan
5,66 Juta. INR
Pertumbuhan Pendapatan Ø5 Tahun
Pertumbuhan EBIT Ø5 Tahun
Pertumbuhan Laba Bersih Ø5 Tahun
Situs Web divislabs.com
Negara
Mata Uang
INR
Penawaran Umum Perdana
25 Jun 1905
ISIN
INE361B01024
CUSIP
Y2076F112
SEDOL
6602518
Kapitalisasi Pasar
Kisaran 52 Minggu
Rasio PEG
10,12
P/E 2026
95,84
P/E 2027
73,07
P/E 2028
62,41
P/E 2029
58,40
P/E 2030
—
P/S
27,46
EV/EBIT
113,70
Rasio P/B
19,55
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
14,63 %
Dividen
Hasil dividen
0,27 %
Hasil Dividen Estimasi
0,27 %
Rasio Pembayaran
36,32 %
Pertumbuhan dividen Ø5T
—
Pembayaran dividen per tahun
1
Dividen dibayarkan sejak
23 tahun
Dividen tidak dipotong sejak
23 tahun
Dividen meningkat sejak
0 tahun
Pajak penahan dividen
20,00 %
Terakhir diperbarui 20 Nov 2026, 14.51

Kelompok Peer Divi's Laboratories

Divi's Laboratories Ticker

BSE · DIVISLAB.BONSE INDIA · DIVISLAB.NS

Divi's Laboratories FIGI

DIVI:IN · BBG000DJVX88DIVI:IB · BBG000DJVXR7DIVI:IS · BBG000DJVYM0DIVI:IG · BBG003NW6WB8

Semua metrik fundamental dan analisis mendalam Divi's Laboratories

Analisis saham kami untuk saham Divi's Laboratories mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Divi's Laboratories. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.